Copaxone PEN from Teva
Copaxone PEN

Press Releases Ypsomed Group

Burgdorf – Teva Pharmaceutical Industries Ltd. (Teva), a global leader in generic medicines with innovative treatments in select areas, including CNS, pain and respiratory, has launched its drug product Copaxone® in the pre-filled autoinjector YpsoMate® from Ypsomed. Copaxone® is used for the treatment of patients with relapsing forms of multiple sclerosis (MS). The collaboration with Teva marks the second commercial market entry of Ypsomed’s autoinjector YpsoMate®.

Ypsomed Headquarters in Burgdorf (Switzerland)

Press Releases Ypsomed Group

Burgdorf – No agreement has been reached between Ypsomed and Insulet Corp., its former supplier of Omnipod® devices on the amount of the expiration fee payable to Ypsomed under the terms of the distribution agreement that expired in June 2018. After unsuccessful attempts to amicably agree on the amount, Ypsomed has decided to file for arbitration. Ypsomed continues to estimate the expiration fee to amount to approximately CHF 50 million.

YpsoMate with proprietary PLAJEX™ syringe for administration of the drug Hulio™ with the active ingredient adalimum.ab

Press Releases Ypsomed Group

Burgdorf – Terumo Corporation (Terumo), a leading global manufacturer and distributor of medical devices, will fill its PLAJEX™ syringe with the drug Hulio® and assemble it with the YpsoMate prefilled autoinjector from Ypsomed. Hulio® is a biosimilar to Humira® (adalimumab) developed by Fujifilm Kyowa Kirin Biologics Co., Ltd. and marketed in the European Union by Mylan N.V. The drug is used in the treatment of various chronic autoimmune diseases.

Notizie Ypsomed Italia

In occasione della Giornata Mondiale del Diabete Ypsomed Italia ha voluto entrare a far parte del tuo cerchio blu, simbolo universale del diabete. Il cerchio si trova spesso in natura ed è quindi stato ampiamente impiegato fin dagli albori dell’umanità, il suo significato è estremamente positivo.

Notizie Ypsomed Italia

Burgdorf - Ypsomed ha aumentato le vendite di 45,3 milioni di franchi svizzeri nel primo semestre 2018/19. Il risultato operativo (EBIT) ammonta a 68,4 milioni di franchi svizzeri. Il risultato include 49,8 milioni di franchi svizzeri di entrate e compensi sugli utili di Insulet Corp. Si continueranno a portare avanti con determinazione le strategie di crescita con i propri prodotti in termini di espansione, innovazione e produzione. La pompa per insulina mylife YpsoPump si sta sviluppando con successo al di là delle aspettative.